UK a Global Leader in Cannabis Clinical Trials, Behind the US, New Report Reveals

A new wave of groundbreaking revelations is set to disrupt the medical cannabis landscape. A report set to be published soon by Prohibition Partners digs into the evolution of medical cannabis research in the past 13 years, indicating that the UK holds the second-highest number of cannabis-related clinical trials, just after the US.

Key Takeaways from the Report:

• Over 400 clinical trials, from the year 2010 to 2023, were analyzed.
• The US led the charge with 54% of the trials.
• The UK, with 13%, secured the second position, outpacing Canada (7.7%) and Israel (6.8%).

The report evidences the swiftness of expansion in the research of medicinal cannabis across different regions, with a notable emphasis on the rising trend of CBD-only clinical trials due to simplified ethical committee approvals.

GW Pharmaceuticals: A Dominant Player

Enter GW Pharmaceuticals, the synonym of innovation and domination within the realm of medicinal cannabis trials. Let it be their contribution to the prolific number of UK-registered trials or the impressive sales figures attached to Epidiolex and Sativex, their influence is impossible to overlook.

The report indicates that their dominance isn’t limited to their clinical trials but extends to an equally impressive hold on cannabis-related patents, most of which are registered in the US or Europe, including 126 counts in the UK.

Their current count stands at nearly 2,000 individual patents, housed within 396 patent families, over half of which are registered in the US and Europe. An unprecedented number of 320 of these patents were published in 2022 alone! CBD, being the primary focus, features in approximately 45% of these novel interventions.

Challengers on the Horizon

The reign of GW may face challengers as companies like US-based Zynerba Pharmaceuticals, Canopy Growth, Tilray, and Echo Pharmaceuticals in the Netherlands, gear up to leave their mark in the cannabis industry.

Prohibition Partners’ analyst, Lawrence Purkiss, the co-author of the report, commented, “GW has shown the size of the potential prize with Epidiolex, and there are many others looking to follow suit.”

What BRITISH CANNABIS™ has to say

As a player in the cannabis industry, It’s fascinating to see this progressive shift towards extensive cannabis-related trials globally. It indeed outlines a promising future, highlighting the potential of cannabis as a therapeutic means. BRITISH CANNABIS™ is eager to contribute to and navigate through this ever-evolving arena of medicinal cannabis.

NOTE: The full report will be available on 30 August 2023. Pre-order your copy today to avail a beneficial 15% discount.

Stay updated with us for more such groundbreaking insights within the cannabis world.